Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

4 Aug 2005 09:43

Torex Retail PLC04 August 2005 Torex Retail plc4 August 2005 FOR IMMEDIATE RELEASE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Wholly Unconditional and Compulsory Acquisition of Outstanding XN Checkout Shares The Board of Torex Retail plc ("Torex Retail") announces that the offer (the"Offer") made by Evolution Securities Limited on behalf of Torex Retail for XNCheckout Holdings PLC ("XN Checkout") has today become wholly unconditional. As at 1.00 p.m. on 3 August 2005, valid acceptances had been received in respectof 26,884,727 XN Checkout Shares (representing approximately 96.03 per cent. ofXN Checkout's issued share capital). Accordingly, Torex Retail will shortly be issuing notices under s.429 CompaniesAct 1985 to XN Checkout Shareholders who have not yet accepted the Offer that itnow intends to exercise its rights to acquire compulsorily all those XN CheckoutShares still outstanding at the expiry of the requisite notice period. In themeantime, the Offer remains open for acceptance until further notice. Notice will also be sent to the Board of XN Checkout requesting that the XNCheckout Directors make an application to AiM for cancellation of the admissionof XN Checkout Shares to trading on AiM. XN Checkout Shareholders who have not yet accepted the Offer should, if theyhold their XN Checkout Shares in Certificated Form, despatch their Forms ofAcceptance as soon as possible or, if they hold their XN Checkout Shares inUncertificated Form accept the Offer electronically through CREST. XN CheckoutShareholders who are in any doubt as to the procedures for acceptance shouldcontact Capita Registrars by telephone on 0870 162 3121 or if calling fromoutside the United Kingdom on +44 208 639 2157. Settlement of consideration to which any XN Checkout Shareholder is entitledwill be effected: (i) in the case of acceptances received (complete in allrespects) by 4 August 2005 within 14 days of this date; or (ii) in the case ofacceptances received (complete in all respects) after 4 August 2005 but whilethe Offer remains open, within 14 days of such receipt. Terms defined in the Offer document dated 8 July 2005 shall, unless the contextrequires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th Oct 20167:00 amRNSInterim Results
28th Sep 20167:00 amRNSNotice of Interim Results
15th Sep 20163:07 pmRNSEdison issues outlook on Tissue Regenix
1st Sep 20167:00 amRNSDermaPure® Medicare coverage in further 10 States
3rd Aug 20167:15 amRNSHardman & Co Research Report on: Tissue Regenix
28th Jul 201610:58 amRNSEdison research outlook on Tissue Regenix (TRX)
18th Jul 201611:20 amRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
11th Jul 20167:00 amRNSOrthopaedics Update
4th Jul 201610:41 amRNSResult of AGM
1st Jul 20167:00 amRNSDermaPure® secures first GPO contract in US
30th Jun 20167:00 amRNSDeferred Annual Bonus Scheme
1st Jun 20167:00 amRNSNew appointment adds clinical expertise to Board
23rd May 20167:00 amRNSPreliminary results for year ended 31 January 2016
20th Apr 20167:00 amRNSNotice of Preliminary Results
14th Apr 20167:00 amRNSChange of Registered Office
24th Mar 20164:40 pmRNSSecond Price Monitoring Extn
24th Mar 20164:35 pmRNSPrice Monitoring Extension
11th Mar 20163:02 pmRNSTR1- NOTIFICATION OF MAJOR INTEREST IN SHARES
9th Mar 20167:00 amRNSFurther Medicare Coverage for DermaPure®
9th Mar 20167:00 amRNS510k market clearance granted for SurgiPureT XD
11th Feb 20167:00 amRNSVP, Orthopaedic, Inc. North America appointed
3rd Feb 20167:00 amRNSDermaPure to be Showcased in Nine Posters at SAWC
26th Jan 201612:21 pmRNSJoint Venture Agreement
25th Jan 20167:00 amRNSHardman & Co Research Report
20th Jan 20167:00 amRNSDermaPure® breaks through $1m sales mark
19th Jan 20167:00 amRNSAppointment of Non-Executive Director
18th Jan 20167:00 amRNSOrthoPureT XM clinical trial enrolment completed
23rd Dec 201512:40 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
4th Dec 20157:00 amRNSOrthoPureT XT implants successfully undertaken
5th Nov 20154:42 pmRNSIssue of equity and total voting rights
26th Oct 20157:00 amRNSIssue of equity and total voting rights
23rd Oct 20157:49 amRNSNon-Executive Director Share Purchase
14th Oct 20154:09 pmRNSEdison initiates coverage of Tissue Regenix
12th Oct 20157:00 amRNSInterim Results
4th Sep 201510:11 amRNSNotice of Interim Results and Capital Markets Day
30th Jul 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
22nd Jul 20157:00 amRNSAdditional US regional distribution agreement
26th Jun 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure®
12th Jun 201512:43 pmRNSResult of AGM
1st Jun 20159:17 amRNSDermaPure saves 18 year old's leg from frost bite
21st May 20159:51 amRNSHolding(s) in Company
20th May 20157:00 amRNSEmployee SAYE Share Plan
12th May 20157:00 amRNSDeferred Annual Bonus Award
11th May 20157:00 amRNSFinal Results
11th May 20157:00 amRNSFurther Medicare Coverage Approval for DermaPure
5th May 20157:02 amRNSUS regional distribution agreement signed
1st May 20154:01 pmRNSHolding(s) in Company
29th Apr 20157:01 amRNSDermaPure US Clinical data to be presented at SAWC
28th Apr 20157:00 amRNSOrthoPureT XT (Tendon) UK Clinical Trial Approval
9th Mar 20152:05 pmRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.